Coronary revascularisation is often associated with myocardial ischaemia-reperfusion injury. Consequently, reperfusion of viable cardiomyocytes and endothelial cells may paradoxically cause cellular injury due to the oxidative and nitrative stress that is associated with the process of re-energising mitochondria that have been previously damaged during ischaemia 1 . Indeed, endothelial injury has been implicated as a major postoperative cause of cardiovascular dysfunction 2 , the severity of which is shown to predict morbid cardiovascular outcomes 3 . Conceptually, damaged vascular endothelium may precipitate further microvascular injury due to a relative decrease in nitric oxide (NO) bio-availability and predominance of endothelin activity.
In humans with normal left ventricular (LV) function, the use of L-arginine cardioplegic arrest during coronary artery graft surgery has been shown to significantly decrease the biochemical markers of oxidative stress 4,5 inflammation 6 and myocardial cell death 4, 7 . Clinically, this has been mirrored by a reduction in the postoperative lengths of stay in the intensive care unit 4, 6 .
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We hypothesised, that in patients with EF <35% undergoing coronary revascularisation with cardiopulmonary bypass, that markers of myocardial and endothelial damage, as well as LV function would be preserved with L-arginine blood cardioplegic arrest when compared to standard blood cardioplegia treatment alone.
MATERIALS AND METHODS
The study was approved by the Human Research and Ethics Committee at The Royal Melbourne Hospital (HREC Ref No. 2003.204 ) and registered at the Australian New Zealand Clinical Trials Registry (registration number: CTRN12610000203055). Written informed consent was obtained from all patients. The study was a simple parallel-randomised trial with 1:1 allocation ratio.
Participants
Adult male and female patients aged between 18 and 80 years of age scheduled for elective primary coronary artery bypass graft surgery requiring cardiopulmonary bypass, with LV ejection fraction less than 35%, as determined by preoperative echocardiography, were enrolled. Patients were excluded if they had renal impairment (creatinine >150 µmol.l -1 ), elevation of liver transaminase enzymes >50% normal, allergy to L-arginine, additional planned cardiac surgery, urgent coronary surgery for evolving myocardial infarction (defined as ongoing chest pain with either cardiac troponin-I level (cTnI)>0.1 µg.l -1 or sinus tachycardia elevation in two or more leads within 48 hours of surgery) or a contraindication to transoesophageal echocardiography. The setting was a single centre tertiary-referral adult cardiac surgery unit.
Interventions
Patients were randomised to receive blood cardioplegia with or without 15 g.l -1 of L-arginine hydrochloride (R-gene 10, Pharmacia and Upjohn Company, Pfizer Inc, New York, NY, USA) added to the crystalloid cardioplegia component. Other than L-arginine, the cardioplegia composition and delivery regimen was identical for all patients. Induction and maintenance cardioplegia consisted of commercial high and low dose crystalloid-cardioplegia solutions respectively (Baxter Viaflex, Baxter Healthcare Pty Ltd, Toongabbie, NSW). Cardioplegic solutions were delivered with blood at ratios of 4:1 and subsequently at 4 to 8:1, depending on the arterial potassium concentration, and at a temperature of 22 to 28°C via both antegrade and retrograde techniques. The L-arginine concentration during induction was 3 g.l -1 and during maintenance varied from 1.5 to 3 g.l -1 of total cardioplegia. Terminal retrograde blood used to reperfuse the heart before separation from cardiopulmonary bypass and was free of L-arginine 8 .
Anaesthetic technique
General anaesthesia consisted of fentanyl (5 to 15 µg.kg -1 ), midazolam (0.025 to 0.2 mg.kg -1 ) and effect-site steering of propofol targetcontrolled intravenous infusion (1.5 to 3.0 µg.ml -1 ) using an Asena PK target-controlled infusion pump (Alaris Medical Australia, Sydney, NSW). All patients received intra-arterial pressure monitoring, pulmonary artery pressure monitoring via a pulmonary artery catheter inserted through the right internal jugular vein and transoesophageal echocardiography. Cardiac output was measured by thermodilution technique. Following cardiopulmonary bypass, milrinone and/or nitroglycerine were administered in order to achieve a cardiac index of 2.0 to 2.5 l.minute -1 .m -2 .
Cardiopulmonary bypass technique
Cardiopulmonary bypass was performed with cannulation of the ascending aorta and venous cannulation with a single two-staged right atrial-caval cannula. Systemic temperature was maintained at 34°C until rewarming was initiated prior to commencement of the last distal coronary anastomosis. Haemoglobin concentration was maintained at or above 70 g.l -1 . The ascending aorta was cross-clamped with a single clamp technique.
Outcome variables
The primary outcome variable was systemic cTnI concentration. Samples were collected from arterial blood, pre-cardiopulmonary bypass and at 15 minutes, 12 hours and 24 hours following removal of the aortic cross-clamp. Concentrations were determined with the ADVIA Centaur ® Assay (TnI-Ultra, Siemens Medical Healthcare Diagnostics, Hayward, CA, USA) 9 .
Secondary outcome variables were measured in order to determine mechanisms and functional action of L-arginine cardioplegic arrest. Coronary sinus blood was collected pre-cardiopulmonary bypass and then at five and 15 minutes following aortic cross-clamp removal. Samples were stored at 2°C and then batch-assayed for cardiac concentrations of malondialdehyde (MDA), xanthine oxidase (XO) and cardiac superoxide dismutase (SOD) activity. MDA is produced as an end result of cellular peroxidation, and is a marker of oxidative stress, while XO and SOD are enzymes responsible for the respective production and metabolism of superoxide, a cytotoxic free radical produced during oxidative stress. Cardiac MDA and XO levels were determined by highperformance liquid chromatography 10, 11 . Cardiac SOD activity was determined using a RANSOD ® superoxide dismutase analysis kit (RANDOX Laboratories Ltd, Ardmore UK). Arterial and coronary sinus lactic acid levels were measured pre-cardiopulmonary bypass and at one, five and 15 minutes after removal of aortic cross-clamp and were determined using an ABL 700 series blood gas analyser (Radiometer, Copenhagen, Denmark). Lactic acid flux, a marker of cardiac anaerobic metabolism, was calculated by subtracting arterial from coronary sinus lactate concentration.
Left ventricular systolic and diastolic function was determined by transoesophageal echocardiography. Systolic LV function was determined by the fractional area change on 2D echocardiography, fractional area change (%) = ([end diastolic area -end systolic area]/ end diastolic area)×100. Diastolic LV function was determined by measuring the lateral mitral annular tissue Doppler velocity (e´) during early diastole. This latter is a load independent measurement of LV relaxation which complies with the American Society of Echocardiography guidelines and standards for determining diastolic function by echocardiography 12 . Pulmonary artery occlusion pressure was used to measure diastolic LV filling pressure. Measurements were made pre-cardiopulmonary bypass and following protamine administration post-cardiopulmonary bypass.
Randomisation
The allocation sequence was generated by computer pseudo-random number generation. Hospital pharmacy performed assignment to intervention group and prepared the blinded and concealed trial solutions. The patients, treating clinicians and researchers were blinded to assignment group.
Statistical models
Patient data were analysed on an intention-totreat protocol. Continuous data is presented as mean±standard deviation (SD). Quantitative data for group×time interactions were examined by a oneway mixed model (within and between subjects) repeated measures analysis of variance. Multisampling asphericity was corrected by applying either the Huynh-Feldt or Greenhouse-Geisser corrections for ε<0.75 and ε>0.75 respectively. Means were compared with independent-samples two-tailed Student's t-test. Categorical data were analysed with either chi-squared or Fisher's exact tests where appropriate. Estimates of power and minimal group size were obtained initially by performing a forward looking power analysis of variance design on cTnI concentration at three levels (time) with a combination of two factors (group) for each time level of cTnI concentration. In a retrospective review of 105 patients undergoing coronary artery surgery at our institution from August to December 2004, cTnI concentration at 24 hours post cardiopulmonary bypass was 
RESULTS
Recruitment and randomisation details are displayed in Figure 1 .
Patient demographic and intraoperative variables were well matched ( Table 1) . One patient in the control group received a non-protocol anaesthetic. Two patients in the L-arginine group had intraoperative findings that required additional surgery to coronary artery grafting (excision of LV aneurysm with mitral valve annuloplasty, and closure of an atrial septal defect). There was no death in either group within the first 30 days of surgery.
Primary outcome
The cTnI concentrations before cardiopulmonary bypass were similar in both groups (control 0.62±1.1 vs L-arginine 0.31±0.9 µg.l -1 ) (P=0.30). Following removal of aortic cross-clamp the cTnI concentrations increased significantly over time in both groups (P <0.0001). The concentrations at 15 minutes (post cross-clamp) and at 12 and 24 hours (post cross-clamp) were control 0.77±1.1, 2.67±1.5 and 2.07±1.6 µg.l -1 vs L-arginine 0.31±1.0, 2.89±1.0 and 1.86±0.8 µg.l -1 ; there was no difference in these post cross-clamp values between groups (P=0.16) ( Figure 2 ).
Secondary outcomes Coronary sinus malondialdehyde, superoxide dismutase and xanthine oxidase
Coronary sinus concentrations of MDA, SOD and XO were similar in both groups before (Figure 3) .
Lactic acid flux
The lactic acid flux was similar in both groups before cardiopulmonary bypass (control -0.03±0.15 vs L-arginine 0.02±0.34 mmol.l -1 ) (P=0.48). Following aortic cross-clamp removal, lactic acid flux was greater in the control group at all time points (control 0.48±0.32, 0.38±0.31 and 0.26±0.30 mmol.l -1 vs L-arginine 0.15±0.23, 0.08±0.19 and -0.15±0.13 mmol.l -1 ) (P=0.0003) (Figure 3 ).
Cardiac function
Fractional area change as measured on transoesophageal echocardiography increased in both groups following cardiopulmonary bypass ([control 29.8±10.2 to 35.2±13.0%] [P=0.008] vs [L-arginine 30.0±9.7 to 39.3±10.6%] [P <0.0001]). However, there was no difference between groups in fractional area change either before or after cardiopulmonary bypass (P=0.16).
The e´ velocity was similar in both groups before cardiopulmonary bypass (control 4.2±1.9 vs L-arginine 3.8±1.2 cm.s -1 ) (P=0.41). Following cardiopulmonary bypass, the e´ velocity had deteriorated in the control group but improved in the L-arginine group (control 3.6±1.2 vs L-arginine 4.6±1.4 cm.s -1 ) (P=0.018). The pulmonary artery occlusion pressure was similar in both groups before cardiopulmonary bypass (control 21±7.6 vs L-arginine 20±6.2 mmHg) (P=0.58). Following cardiopulmonary bypass this had significantly increased in the control group, but remained unchanged in the L-arginine group (control 25±8.9 vs L-arginine 20±5.0 mmHg) (P=0.01) (Figure 4 ).
DISCUSSION
The primary outcome from this study indicates that L-arginine cardioplegic arrest does not alter biochemical markers of myocardial injury as measured by cTnI at 12 and 24 hours post removal of aortic cross-clamp in patients undergoing coronary artery graft surgery with reduced LV function (EF<35%). However despite this negative finding on cTnI, L-arginine cardioplegia was found to significantly attenuate myocardial oxidative stress and was associated with a reduction in diastolic dysfunction immediately after cessation of cardiopulmonary bypass. We were unable to detect a difference in cTnI levels in this cohort of patients. However this result is not unusual, as the administration of L-arginine as a myocardial protective agent has produced conflicting results. For instance, the administration of oral L-arginine to post sinus tachycardia elevation myocardial infarct patients resulted in no improvement in LV systolic function and a statistically increased mortality in the treatment group 13 . When delivered in cardioplegia, animal data indicated that L-arginine at concentrations of 4 mmol.l -1 was safe and efficacious: however, when administered at concentrations above 5 mmol.l -1 it was found to be less effective 14 . In support of this finding, a recent dose finding study in humans revealed that L-arginine administered in undiluted cardioplegia had maximal suppression of myocardial lactate production at the lower concentration of 4 mmol.l -1 when compared to higher concentrations of 6 mmol.l -1 15 . Moreover, L-arginine cardioplegic arrest in humans in which 1 g L-arginine was delivered with induction cardioplegia (which corresponds to a 7 to 8 mmol.l -1 concentration), did not lead to any measurable difference in cTnI 16 . In contrast to these negative findings, other investigators report significant reductions in both cardiac troponin-T and creatinine kinase at significantly higher concentrations of L-arginine cardioplegia 4, 6, 7 . The amount of L-arginine that was delivered in cardioplegia, once diluted in blood, in our study averaged 2.4±0.5 g.l -1 , corresponding to a concentration of 13.7±2.7 mmol.l -1 and similar to the concentrations delivered in previous clinical investigations 4, 7 . It is interesting to note that our study successfully achieved myocardial lactate suppression with a high relative concentration of L-arginine which suggests that myocardial protection as well as the effects on myocardial aerobic metabolism may be dependent upon more factors than simply the absolute amount of L-arginine delivered in cardioplegia and the concentration at which it is delivered.
A confounding variable that has recently been postulated to contribute to the disparate results seen with L-arginine cardioplegia is the presence and activity of the enzyme arginase within the myocardium. This enzyme is responsible for the metabolism of L-arginine to L-ornithine and urea. Recent data has demonstrated that it is upregulated especially in the ischaemic myocardium during ischaemia-reperfusion 17 and may in fact compete with endothelial nitric oxide synthase (eNOS) for arginine as a substrate, thus resulting in reduced NO production 18 . Although our study made no measure of myocardial arginase activity, the lack of protection evident in this particular group of patients with ischaemic cardiomyopathy is consistent with this overall net effect. Furthermore, no previous human study has controlled for arginase activity in the human myocardium. Clearly, further investigation in this area is warranted.
Additional observations involving the functional mechanism of L-arginine upon myocardial oxidative stress can be made from this study. The secondary outcome variable findings indicate that L-arginine cardioplegia mechanistically reduces oxidative injury and preserves diastolic function and may be secondary to effects on the myocardium or endothelium that are independent of those responsible for reducing cardiomyocyte death. L-arginine caused an immediate reduction in cardiac MDA following reperfusion of the myocardium. Malondialdehyde is a product of enzymatic and free radical-induced lipid peroxidation and is frequently used as a surrogate measure of oxidative and/or nitrative stress. Ischaemic depletion of the substrates and cofactors of eNOS causes a decoupling in its function and subsequent production of cytotoxic superoxide. Consequent to this, superoxide may combine avidly with residual NO to form the damaging free radical peroxynitrite and thus lead to lipid peroxidative injury. In order to function appropriately, eNOS requires an abundant extracellular supply of L-arginine despite what may be considered sufficient quantities of intracellular L-arginine (L-arginine paradox) 19 . In support of this concept, directed delivery of extracellular L-arginine has been shown to prevent similar uncoupling of constitutive eNOS 20 and is consistent with the reduction in myocardial MDA seen in this particular study. This effect is most likely attributable to an L-arginine/NO mediated increase in myocardial SOD activity, which has been previously demonstrated 4, 5 , and which, in this particular study, was observed to increase immediately following reperfusion of the myocardium. Superoxide is also created by other enzymatic actions, in particular that of XO, which similar to eNOS, is primarily localised in the cardiac endothelial cells 21 . L-arginine blood cardioplegia had little effect on the activity of this enzyme and the lower levels of cardiac MDA cannot be attributed to differences in production of superoxide due to induced XO activity.
The improvement in diastolic but not systolic function is consistent with previous reports of L-arginine cardioplegia that also have failed to show an improvement in cardiac systolic function despite actual reductions in cardiac troponin T concentrations 6 . In our study, diastolic functional improvement was indicated by a greater lateral mitral annular tissue e´ velocity during early diastole in the L-arginine group after cardiopulmonary bypass, and was reflected in the same group by a lower left atrial filling pressure as estimated by the pulmonary artery occlusion pressure. This result suggests that L-arginine or NO may have a direct effect upon diastolic function itself. A positive lusitropic effect of NO has previously been reported in contracting papillary muscle strips, isolated ejecting guineapig heart and following intracoronary infusions in humans [22] [23] [24] .
Limitations of this study are as follows. The cTnI concentrations in this study, in both groups, were significantly lower than the pilot data concentrations that were used to calculate sample size, despite identical clinical practice. In particular, this study was powered to detect a 50% reduction in differences between groups in cTnI levels in the first postsurgical 24 hour period. We therefore cannot rule out that with a greater sample size it may have been possible to identify a smaller (30 to 40%) difference in cTnI levels between groups. However, based on our measured results this would correspond to cTnI levels of 1.67±1.01 to 1.95±1.38 µg.l -1 . Given the low postoperative cTnI levels demonstrated in both groups, it could be argued that small differences such as these would not be considered clinically relevant. Plasma concentrations of cTnI following coronary artery surgery are indeed heterogeneous and exhibit institutional variation: however, the postoperative cTnI levels seen in our study are within the expected post surgical ranges previously reported 25 and are consistent with those seen in other investigations of L-arginine cardioplegia 16 . We cannot conclude from the data as to the site of action of L-arginine, in particular as to whether it was within cardiomyocytes or endothelial cells or both. Furthermore, as no measurement of nitrite extraction was made, we were not able to conclusively identify whether L-arginine exerted its lusitropic and anti-oxidative effects either directly or indirectly as a result of NO induction.
CONCLUSION
This investigation establishes that L-arginine cardioplegic arrest does not effect cTnI concentration in the first 24 hour postoperative period when administered to patients with reduced LV function (EF <35%) undergoing coronary artery surgery. However, it was seen to result in a clear reduction in oxidative injury and led to a more rapid return in myocardial aerobic metabolism with an associated improvement in early cardiac diastolic function. As there was no difference in myocardial injury or change in early systolic cardiac function, these observations appear to be independent of a direct myocardial protective effect of L-arginine cardioplegia.
